Jascayd (nerandomilast) - Boehringer Ingelheim
Characterization of Diarrhea Adverse Events with Nerandomilast in Patients with Autoimmune Interstitial Lung Disease and Progressive Pulmonary Fibrosis in the FIBRONEER-ILD Trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1774; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available 
Adverse events • Clinical • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3568704
 
Anna-Maria Hoffmann-Vold, MD, PhD
 
Sep 8, 2026
 
Prev Next